MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

HBsAg seroclearance

  • Home
  • HBsAg seroclearance
Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen
Posted inGastroenterology news Oncology

Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen

Posted by By MedXY 07/14/2026
This study evaluates the long-term incidence of liver cancer in chronic hepatitis B patients who clear hepatitis B surface antigen, finding significantly reduced cancer risk in younger patients without cirrhosis.
Read More
HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation
Posted inGastroenterology Infectious Diseases news

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation

Posted by By MedXY 06/10/2026
In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint.
Read More
  • Enhancing Inter-Visit Care in Internal Medicine Residency: Integrating Structural Support and Educational Curriculum
  • Respiratory Syncytial Virus Vaccine Effectiveness in Medicare Beneficiaries Residing in Nursing Homes: A Comprehensive Review
  • Periconceptional Vitamin B12 and Folate Levels in Parents Linked to Birth Defect Risk Reduction: Insights from a Large Prospective Cohort
  • TP53 Mutations in Acute Myeloid Leukemia: Impact on Outcomes Post-Allogeneic Hematopoietic Cell Transplantation
  • Pre-Transplant KMT2A-PTD Measurable Residual Disease as a Prognostic Biomarker in Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top